Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating
On February 4, Mizuho analyst Uy Ear lowered the firm’s price target on Evolus, Inc.
Evolus Inc. (EOLS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 5,820,649 | $38,707,316 | +2% | 1.28% |
| 2. | Stonepine Capital Timothy P. Lynch | 1,631,588 | $10,850,060 | +7% | 7.92% |
| 3. | Soleus Capital Guy Levy | 1,070,000 | $7,115,500 | -27% | 0.26% |
| 4. | Renaissance Technologies Jim Simons | 799,900 | $5,319,335 | +28% | 0.01% |
| 5. | Squarepoint Ops LLC Maxime Fortin (Cio) | 174,346 | $1,159,401 | +324% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.82 | 30,000 | $204,486.00 | 88,629 | 2025-08-15 | Filing | |
| $9.45 | 20,000 | $189,000.00 | 50,378 | 2025-06-09 | Filing | |
| $7.41 | 174,967 | $1,296,505.47 | 275,550 | 2023-08-15 | Filing | |
| $11.11 | 14,043 | $156,064.07 | 7,296,543 | 2021-08-13 | Filing | |
| $10.99 | 23,000 | $252,774.60 | 7,282,500 | 2021-08-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.15 | 10,539 | $75,361.23 | 354,388 | 2025-12-22 | Filing | |
| $7.15 | 2,261 | $16,167.73 | 356,821 | 2025-12-22 | Filing | |
| $7.51 | 5,722 | $42,972.22 | 89,949 | 2025-08-22 | Filing | |
| $9.89 | 16,582 | $164,054.02 | 364,927 | 2025-06-16 | Filing | |
| $10.05 | 111,323 | $1,119,141.25 | 381,509 | 2025-06-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,095,300 | $27,233,746 | 0% | |
| 2. | 3,341,804 | $22,222,997 | 0% | |
| 3. | 2,630,665 | $17,493,922 | 0.47% | |
| 4. | 1,574,851 | $10,472,759 | 0% | |
| 5. | 1,386,248 | $9,221,169 | 0% |
News See All
11 High Growth Micro-cap Stocks to Buy
Investing in stocks of companies with market values under $300 million, otherwise known as micro-cap stocks, offers a unique opportunity to get in early on fast-growing businesses.
Mizuho Cuts Evolus (EOLS) Estimates for Jeuveau/Evolysse on Waning Consumer Sentiment and Inflationary Pressure on Elective Aesthetics
Evolus Inc. (NASDAQ:EOLS) is one of the stocks that will double in 2026.
20 Stocks That Will Double in 2026
On December 8, Kevin Mahn of Hennion & Walsh appeared on CNBC's 'Closing Bell Overtime' to discuss the potential for another bullish year, but with more volatility.
Evolus, Inc. (NASDAQ:EOLS) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for standing by. Welcome to Evolus' Third Quarter Earnings Conference Call.
Evolus, Inc. (NASDAQ:EOLS) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for standing by. Welcome to Evolus' Second Quarter Earnings Conference Call.
Evolus, Inc. (EOLS): A Bull Case Theory
We came across a bullish thesis on Evolus, Inc. (EOLS) on Substack by Greg ┃The Elevator Pitch. In this article, we will summarize the bulls’ thesis on EOLS. Evolus, Inc.
Evolus, Inc. (NASDAQ:EOLS) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, everyone. And thank you for standing by. Welcome to Evolus's First Quarter Earnings Conference Call. As a reminder, today's conference is being recorded and webcast live.
Evolus, Inc. (NASDAQ:EOLS) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for standing by. Welcome to Evolus Fourth Quarter and Full Year 2024 Earnings Conference Call.
12 Best Small Cap Pharma Stocks to Buy Now
Emily Field, Head of European Pharma Research at Barclays, spoke on CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical ...
Hedge Fund Resource Center Billionaire Hedge Funds
